Sign in now to see personalised content appear here.
You can also see your reading history and subscription details on your subscriber page.
Detailed validation protocols streamline optimisation and validation, saving time and reagents
Cobra developed the cell line to express agonistic CD40 antibodies for an immuno-oncology application using its maxXpress platform
CiteAb lists more than 1.5 million antibodies from 92 suppliers
Using Wacker E.coli-based ESETEC secretion technology
For process development and early stage clinical supply of monoclonal antibodies
For the production of PASylated therapeutic proteins
Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies